U.S. markets closed

Kintara Therapeutics, Inc. (DMPI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3400+0.0900 (+7.20%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.2500
Open1.2200
Bid0.0000 x 1200
Ask0.0000 x 900
Day's Range1.1700 - 1.3500
52 Week Range0.3800 - 1.9500
Volume1,331,424
Avg. Volume433,201
Market Cap15.354M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateSep 08, 2020 - Sep 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020
      PR Newswire

      Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020

      Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that Saiid Zarrabian, Chief Executive Officer of Kintara, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:00 PM ET followed by a live Q&A; session with registered investors and other conference attendees.

    • Kintara Therapeutics Announces Closing of Additional $2.2 Million Private Placement Priced at the Market
      PR Newswire

      Kintara Therapeutics Announces Closing of Additional $2.2 Million Private Placement Priced at the Market

      Kintara Therapeutics, Inc. ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has closed its previously announced private placement with investors providing for the sale and issuance of 2,185 shares of its Series C Convertible Preferred Stock (the "Preferred Stock") at a purchase price of $1,000 per share priced at-the-market under the rules of the Nasdaq Stock Market. The Preferred Stock is convertible into shares of the Company's common stock at a conversion price of $1.214 per share. The closing resulted in gross proceeds to the Company of approximately $2.2 million, which is in addition to the $19.6 million of gross proceeds previously announced in connection with the initial closing of the private placement. The Preferred Stock accrues dividends as previously announced.

    • Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market
      PR Newswire

      Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market

      Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 2,435 shares of its Series C Convertible Preferred Stock (the "Preferred Stock") at a purchase price of $1,000 per share in a private placement offering priced at-the-market under the rules of the Nasdaq Stock Market. The Preferred Stock is convertible into shares of Kintara common stock at a conversion price of $1.214 per share. The offering is expected to result in gross proceeds to Kintara of up to approximately $2.4 million which is in addition to the $19.6 million previously announced. The Preferred Stock accrues dividends as previously announced.